Health
New Covid-19 vaccine demonstrates ‘89% efficacy’ with UK having 60m orders – expressandstar.com
A trial was carried out in conjunction with the UK Government’s Vaccine Taskforce.
An experimental Covid-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.
The UK has secured access to 60 million doses of the vaccine, called NVX-CoV2373.
The protein-based vaccine candidate was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27% were older than 65, Novavax said.
NVX-CoV2373 is the first vaccine…
-
General14 hours agoRSL NSW president Mick Bainbridge and three board members resign in wake of 7.30 investigation into conflicts of interest
-
General18 hours agoSelf-taught child drummer makes rock band debut with The Living End
-
Noosa News22 hours agoWave of cruises headed for Sunshine Coast this summer
-
Noosa News18 hours agoOne Nation leader Pauline Hanson calls out supermarket giants for ‘fleecing’ customers with ‘flimsy’ paper bags